Fibromuscular dysplasia secondary prevention

Fibromuscular dysplasia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Fibromuscular dysplasia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiorgram
X-ray
CT
MRI
Arteriography
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Management Guidelines
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
ASA/ACCF/AHA Guideline Recommendations
Management of Patients With Fibromuscular Dysplasia of the Extracranial Carotid Arteries
Case Studies
Case #1
Fibromuscular dysplasia secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Fibromuscular dysplasia secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Fibromuscular dysplasia secondary prevention
CDC on Fibromuscular dysplasia secondary prevention
Fibromuscular dysplasia secondary prevention in the news
Blogs on Fibromuscular dysplasia secondary prevention
Directions to Hospitals Treating Fibromuscular dysplasia
Risk calculators and risk factors for Fibromuscular dysplasia secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

• Antiplatelet therapy is an integral component of effective

secondary prevention after noncardioembolic ischemic stroke.

• Effective measures for the secondary prevention of [disease name] include:
  • [Strategy 1]
  • [Strategy 2]
  • [Strategy 3]